Michael Gladstone is Director at Day One Biopharmaceuticals, Inc. (DAWN). They have made 1 open-market trade across 1 company since 2022, most recently 2022-06-17.
CIK 0001864256
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $11.5M since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DAWN | 766,667 | $16.5M |
Shares reported on the most recent Form 4, priced at the 2022-06-22 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DAWN | BUY | 2022-06-17 | 2022-06-22 | $15.00 | $11.5M | +18.6% | +10.7% | +20.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.